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In this issue of Haematologica, Godavarthy et al.
1 describe
how the expression of CD44 on the surface of leukemic
stem cells (LSC) and E-selectin on bone marrow (BM)
endothelium are essential for the engraftment of LSC with-
in the BM niche. They show how this interaction can pro-
vide the LSC with protection from imatinib treatment.
Importantly, disruption of this axis using an E-selectin
inhibitor in combination with imatinib prevents LSC bind-
ing to the endothelium and demonstrates superior eradica-
tion of LSC in chronic myeloid leukemia (CML) compared
with imatinib alone. 
CML has been well characterized for a number of years,
since the discovery of the Philadelphia chromosome and
associated aberrant BCR-ABL signaling. This led to the rev-
olutionary development of BCR-ABL-specific tyrosine
kinase inhibitors such as imatinib. Tyrosine kinase
inhibitors are highly effective at reducing the leukemic bur-
den and disease progression, inducing remission and pro-
longing survival of patients with chronic phase CML.2
Although very good control over the disease is gained in
most chronic phase CML patients with tyrosine kinase
inhibitor treatment, eradication of the LSC population,
which sustains and repopulates the disease in patients,
remains elusive.3
It has been established that the BM niche provides a sanc-
tuary for LSC in which to thrive and avoid pharmacological
interventions. There have been many studies showing how
the niche adapts and is exploited during leukemic transfor-
mation.4-6 By gaining, a better understanding of the interac-
tions between LSC and their microenvironment, it may be
possible to distinguish factors that favor survival of the
leukemic cells and identify targets for improved drug ther-
apy. One such strategy is to inhibit the homing and engraft-
ment of LSC within the BM niche, without affecting nor-
mal hematopoietic stem cells (HSC).7
The BM microenvironment is complex, due to the array
of different cell types which reside there, including osteo-
lineage cells, mesenchymal stem cells, endothelial cells,
neurons and hematopoietic cells.8 In order to control and
maintain homeostasis of the healthy BM niche, a multitude
of cytokines and chemokines help determine HSC fate.8 In
normal hematopoiesis homing and engraftment of HSC
within the BM is a highly coordinated multistep process
that requires activation of different adhesion receptors to
maintain tight regulation. Selectins and integrins are very
important within this process.9,10 Expression of integrins
allows HSC to bind to vascular cell adhesion molecule-1 on
BM endothelium and fibronectin on the extracellular
matrix. Integrins, such as VLA4, also interact with E- and P-
selectins, which are found constitutively expressed on the
BM endothelium, and this interaction mediates HSC rolling
and homing.10 Another important factor within this process
is CXCL12; this chemkine functions as an HSC chemoat-
tractant through its receptor CXCR4, which through
crosstalk with β1 and β2 integrins, mediates HSC homing
and is required for stable engraftment.9 CD44 has also been
linked to HSC homing; however, HSC that do not express
CD44 can still home and engraft normally.11
In studies comparing the homing and engraftment of
CML LSC to normal HSC, it has been shown that patients
with CML have several adhesion abnormalities.12,13 LSC
have defective β1 integrin function, despite normal expres-
sion of VLA4 and VLA5, which decreases LSC adhesion to
BM stroma.13 It has also been shown that primary CML
progenitor cells have reduced CXCR4 expression and
impaired chemotaxis towards CXCL12, as well as reduced
CXCL12-mediated integrin adhesion.12 Despite these func-
tional defects, LSC can still home and engraft within the
BM and therefore must use alternative mechanisms. 
Godavarthy et al.1 demonstrate a novel reciprocal link
between the external cues from the BM microenvironment
and BCR-ABL-specific LSC-intrinsic pathways. They show
how this leads to modulation of the expression of LSC
adhesion molecules and alters interactions with the vascu-
lar niche. The authors confirm the interaction of BCR-ABL+
cells and the vascular endothelium by using very sophisti-
cated in vivo microscopy of the calvarium of mice injected
with human CML leukocytes. Using time-lapse imaging,
they found that the contact time of the leukemic cells to the
BM endothelium was reduced in mice treated with an E-
selectin inhibitor (GMI-1271). 
The authors replicated these findings in a transgenic
model, showing that BCR-ABL+ cells were situated signifi-
cantly further away from the endothelium if treated with
GMI-1271 and imatinib. Furthermore, after treatment with
GMI-1271 and imatinib, mice had improved survival, and
demonstrated reduced numbers of CML-initiating clones,
impaired short-term homing to the spleen and the BM,
reduced leukocyte counts, BCR-ABL+ myeloid cell counts
and spleen size. Further studies showed that inhibition of E-
selectin led to non-adhesion and an increase of Scl/Tal1
expression in BCR-ABL+ leukemia-initiating cells (LIC) in
vitro. Additionally, Scl/Tal1 negatively regulated the expres-
sion of CD44 on LIC, and overexpression of Scl/Tal1 on LIC
led to prolongation of survival in a murine model of CML,
similar to the improved survival with CD44-deficient
CML-initiating cells previously demonstrated by Krause et
al.14
In vitro experiments demonstrated that CD44 was highly
expressed in BCR-ABL+ cells compared to BCR-ABL– cells,
and that when BCR-ABL+ cells were treated with GMI-
1271 alone or in combination with imatinib there was an
increase in cells in G2-S-M phase and a decrease in the G0
phase of the cell cycle. This coincided with an increase in
cell cycle promoter CDK6 and decreased expression of cell
cycle inhibitor p16. Furthermore, BCR-ABL1 phosphorylat-
ed SCL/TAL1 via the AKT signaling pathway. SCL/TAL1
regulated the activity of the CD44 regulatory element by
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acting as a transcriptional repressor leading to decreased
expression of CD44, decreased adhesion to the vascular
niche and an increase in cycling LSC.
Interestingly, higher expression of CD44 was demon-
strated in BCR-ABL cells specifically harboring the T315I
mutation, which correlated with increased binding to E-
selectin, with a larger amount of adherent cells in G0. The
authors suggest that the increased expression of CD44 and
increased binding to E-selectin may contribute to LSC dor-
mancy and resistance to tyrosine kinase inhibitors. 
Finally, relevance to human CML was established as
leukocytes from patients with CML had higher transcrip-
tional expression of SCL/TAL1 and lower CD44 expression
compared to those from healthy individuals. Analyses of
published datasets suggest a trend that expression of
SCL/TAL1 and CD44 may correlate with disease stage and
survival in CML patients; however, larger cohorts and fur-
ther experimental data are required to confirm this. 
The important experiments presented by Godavarthy et
al. establish the mechanism of increased expression of
CD44 on BCR-ABL1+ cells. They further showed that dislo-
cation of BCR-ABL1+ cells from the niche, via inhibition of
E-selectin binding, increased BCR-ABL+ cell cycle progres-
sion and increased responsiveness to imatinib therapy.1
Inhibition of E-selectin has been shown to have therapeu-
tic utility in other cancer types, such as acute myeloid
leukemia and solid tumors in which it is thought to have a
role in metastasis.15 In acute myeloid leukemia, the
leukemic blast cells bind to E-selectin on the endothelium
and this activates leukemic pathways that contribute to
chemotherapy resistance.16 Currently, GMI-1271 is in a
phase I/II clinical trial to treat acute myeloid leukemia in
combination with chemotherapy to disrupt leukemia sur-
vival pathways and sensitize the leukemic cells to
chemotherapy (ClinicalTrials.gov Identifier: NCT02306291)  
E-selectin has also been implicated in the development of
metastasis to the lungs from primary solid tumors, such as
breast17 and colon18 cancer. It is hypothesized that, during
the premetastatic stage, the primary tumors secrete soluble
factors, which induce an inflammatory response in the
Figure 1. This schematic demonstrates the effects of E-selectin inhibition within the bone marrow microenvironment and the impact upon chronic myeloid
leukemia stem cells and mechanistically how this is controlled by the  SCL/TAL1 – CD44 axis. HPC: hematopoietic progenitor cell; HSC; hematopoietic stem cell;
LSC: leukemic stem cell.
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blood vessels and activate E-selectin on the endothelium,
allowing engraftment of immune progenitor cells. This ini-
tial binding of E-selectin to its ligand confers firm adhesion,
and triggers signaling that leads to permabilization of the
endothelium through the dissociation of VE-cadherin/β-
catenin. In an attempt to counteract metastasis, the E-
selectin inhibitor GMI-1271 is currently being tested in pre-
clinical models and is showing high efficacy.17 As well as
being a therapeutic target, E-selectin is also being screened
as a potential biomarker for disease progression and metas-
tasis.19
The BM microenvironment is a developing research
focus which is showing great importance in disease patho-
physiology. Advances in technology, such as the time-lapse
intra-vital imaging used in the study by Godavarthy et al.,1
are enabling a greater understanding of the interactions and
mechanisms involved in cellular microenvironments This
type of pioneering microscopy allows us to see interactions
between leukemic cells and the niche, and is providing
powerful data, as exemplified by this study as well as many
others.13 Enriching these data, single-cell RNA-sequencing
allows for the analysis of the different cell types within the
niche, evaluation of their transcriptional regulation and a
view of how they may contribute to disease progression,
providing important information which may have been
masked using bulk sequencing approaches.20 Through these
studies, we continue to build upon our knowledge of the
pathophysiology of CML and come ever closer to finding a
way of eradicating quiescent LSC. 
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